TriSalus Life Sciences Past Earnings Performance
Past criteria checks 0/6
TriSalus Life Sciences's earnings have been declining at an average annual rate of -25%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 33% per year.
Key information
-25.0%
Earnings growth rate
-9.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 33.0% |
| Return on equity | n/a |
| Net Margin | -341.8% |
| Next Earnings Update | 15 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How TriSalus Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 19 | -63 | 41 | 30 |
| 30 Sep 23 | 16 | -52 | 33 | 28 |
| 30 Jun 23 | 15 | -59 | 30 | 24 |
| 31 Mar 23 | 13 | -51 | 27 | 22 |
| 31 Dec 22 | 12 | -50 | 25 | 21 |
| 30 Sep 22 | 12 | -32 | 22 | 19 |
| 31 Dec 21 | 8 | -29 | 17 | 14 |
| 31 Dec 20 | 5 | -32 | 13 | 16 |
Quality Earnings: TLSI is currently unprofitable.
Growing Profit Margin: TLSI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if TLSI's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare TLSI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TLSI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.9%).
Return on Equity
High ROE: TLSI's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.